ResMed Inc (ASX: RMD) is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.32% at lunch.
The BetaShares Global Sustainability Leaders ETF (ASX:ETHI) and the BetaShares Australian Sustainability Leaders ETF (ASX:FAIR) are two options.
The healthcare industry benefits from an ageing population. I look at two ASX shares, ResMed Inc (ASX:RMD) and CSL Limited (ASX:CSL).
The 52-week high price for Cochlear Limited (ASX: COH) shares is $221.44. Up almost 20% in the last three months, could Cochlear reach these highs again?
Forget CSL shares, Cochlear Ltd (ASX: COH), Nanosonics Ltd (ASX:NAN) and ResMed Inc (ASX:RMD) shares are amongst my top three ASX healthcare shares.
The ResMed Inc. (ASX:RMD) share price is up as much as 10.5% to a high of $16.25 after handing down the third quarter results with revenue up 12%.
ResMed Inc (ASX:RMD) shares and TPG Telecom Ltd (ASX:TPM) shares are two ASX blue-chips that have seen steep drops recently.
With the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO) down 1% some investors might be asking ‘what on earth has happened to OncoSil Medical Ltd (ASX: OSL)’?
After 2018 saw the S&P/ASX 200 (INDEXASX:XJO) drop by 6.9%, investors were offered some relief in January with the market rebounding to finish the month 4.25% higher.
